Verrica Pharmaceuticals I... (VRCA)
0.71
-0.01 (-0.84%)
At close: Jan 28, 2025, 2:53 PM
undefined% (undefined)
| Bid | 0.7 |
| Market Cap | 63.96M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.84 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.71 |
| Volume | 79,730 |
| Avg. Volume (20D) | 735,316 |
| Open | 0.72 |
| Previous Close | 0.72 |
| Day's Range | 0.69 - 0.74 |
| 52-Week Range | 0.61 - 11.41 |
| Beta | undefined |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based p...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2018
Employees 100
Stock Exchange NASDAQ
Ticker Symbol VRCA
Website https://www.verrica.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VRCA stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 749.62% from the latest price.
Buy 20.00%
Hold 80.00%
Sell 0.00%
Next Earnings Release
Verrica Pharmaceuticals Inc. is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of $1.30M, reflecting a -34.61% YoY shrinking and earnings per share of -0.24, making a -54.72% decrease YoY.
Analysts project revenue of $1.30M, reflecting a -34.61% YoY shrinking and earnings per share of -0.24, making a -54.72% decrease YoY.
2 months ago
-0.29%
Verrica Pharmaceuticals shares are trading lower a...
Unlock content with
Pro Subscription
2 months ago
-44.23%
Verrica Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results, announced senior leadership changes, and is exploring strategies to strengthen its balance sheet. Additionally, RBC Capital downgraded the stock from Outperform to Sector Perform and cut its price target from $11 to $2.
